What is Northwest Biotherapeutics Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Northwest Biotherapeutics's interest expense for the
three
months ended in Sep. 2024 was $ -2.08 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Sep. 2024 was $-6.52 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Northwest Biotherapeutics's Operating Income for the
three
months ended in Sep. 2024 was $ -14.80 Mil. Northwest Biotherapeutics's Interest Expense for the
three
months ended in Sep. 2024 was $ -2.08 Mil.
Northwest Biotherapeutics did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Northwest Biotherapeutics Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.52 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Northwest Biotherapeutics (OTCPK:NWBO) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Northwest Biotherapeutics's Interest Expense for the
three
months ended in Sep. 2024 was $-2.08 Mil. Its
Operating Income
for the
three
months ended in Sep. 2024 was $-14.80 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Sep. 2024 was $29.30 Mil.
Northwest Biotherapeutics's Interest Coverage for the quarter that ended in Sep. 2024 is calculated as
| Northwest Biotherapeutics did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Northwest Biotherapeutics Business Description
Traded in Other Exchanges
Address
4800 Montgomery Lane, Suite 800, Bethesda, MD, USA, 20814
Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S. Food and Drug Administration.
Executives
| Navid Malik |
director |
1 CHOLMELEY PARK, HIGHGATE, LONDON X0 N6 5ET |
| Marnix L Bosch |
officer: Chief Technical Officer |
22322 20TH AVENUE SE, STE 250, BOTHELL WA 98021 |
| Alton L Boynton |
director, officer: Chief Scientific Officer |
22322 20TH AVENUE SE, STE 150, BOTHELL WA 98021 |
| Leslie J. Goldman |
officer: See Remarks |
C/O NORTHWEST BIOTHERAPEUTICS, INC., 4800 MONTGOMERY LANE, SUITE 800, NEW YORK NY 20814 |
| Linda F Powers |
director, 10 percent owner, officer: President and CEO |
7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814 |
| Jerry J Jasinowski |
director |
C/O HARSCO CORP, P O BOX 8888, CAMP HILL PA 17001-8888 |
| Jean M. Davis |
officer: See Remarks |
4800 MONTGOMERY LANE, SUITE 800, BETHESDA MD 20814 |
| Susan B Bayh |
director |
WELLPOINT, INC., 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204 |
| Black Cofer |
director |
4800 MONTGOMERY LANE, SUITE 800, BETHESDA MD 20814 |
| Woodford Investment Management Llp |
10 percent owner |
27 OLD GLOUCESTER STREET, LONDON X0 WC1N 3AX |
| Cf Woodford Equity Income Fund |
10 percent owner |
C/O WOODFORD INVESTMENT MANAGEMENT LTD, 9400 GARSINGTON ROAD, OXFORD X0 OX4 2HN |
| Cognate Bioservices, Inc. |
10 percent owner |
7513 CONNELLEY DRIVE, HANOVER MD 21076 |
| Robert A Farmer |
director |
10205 COLLINS AVE PENTHOUSE 6, MIAMI BEACH FL 33154 |
| Toucan General Ii, Llc |
10 percent owner |
7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814 |
| Hemphill Robert F Jr. |
10 percent owner |
7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814 |
Northwest Biotherapeutics Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NWBO has been successfully added to your 